Overview
Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate. Triamcinolone was granted FDA approval on 3 December 1957. In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval - for the treatment of patients with macular edema associated with uveitis.
Indication
肾上腺皮质激素类药。主要用于过敏性与自身免疫性炎症性疾病。由于本品潴钠作用较弱，故一般不用作肾上腺皮质功能减退的替代治疗。
Associated Conditions
- Acne
- Acne Vulgaris
- Acute Gouty Arthritis
- Allergic Contact Dermatitis
- Allergic Rhinitis (AR)
- Allergic Skin Reaction
- Alopecia Areata (AA)
- Ankylosing Spondylitis (AS)
- Aphthous Stomatitis
- Asthma
- Atopic Dermatitis
- Autoimmune Hemolytic Anemia
- Berylliosis
- Bullous dermatitis herpetiformis
- Chronic Eczema
- Chronic Inflammatory Skin Diseases
- Congenital Adrenal Hyperplasia (CAH)
- Congenital Hypoplastic Anemia
- Contact Dermatitis
- Crohn's Disease (CD)
- Dental Cavity
- Dermatitis
- Dermatomyositis (DM)
- Diaper Rash
- Discoid Lupus Erythematosus (DLE)
- Edema of the cerebrum
- Epicondylitis
- Erythroderma
- Fungal Infections
- Fungal infectious disorders of the Beard
- Fungal skin infection
- Gingivitis
- Haemorrhoids
- Hemangiomas
- Hypercalcemia
- Inflammation of Mouth
- Intertrigo
- Itching of the Anus
- Itching of the External Genitalia
- Itching of the Foot
- Itching of the genitals
- Itching of the hand
- Juvenile Idiopathic Arthritis (JIA)
- Keloids Scars
- Leukemias
- Lichen Planus (LP)
- Lichen simplex chronicus
- Lymphoma
- Macular Edema
- Mycosis Fungoides (MF)
- Mycotic Eczema
- Necrobiosis lipoidica diabeticorum
- Neurodermatitis
- Nummular Dermatitis
- Ocular Inflammation
- Ophthalmia, Sympathetic
- Oral Erosive Lichen Planus
- Otitis Externa
- Pemphigus
- Pericarditis
- Polymyositis
- Postherpetic Neuralgia
- Primary adrenocortical insufficiency
- Proteinuria
- Psoriasis Vulgaris (Plaque Psoriasis)
- Psoriatic Arthritis
- Psoriatic plaque
- Pure Red Cell Aplasia
- Purulent Wounds
- Pyoderma caused by susceptible bacteria
- Regional Enteritis
- Rheumatoid Arthritis
- Ringworm Folliculitis
- Seborrheic Dermatitis
- Seborrheic Dermatitis, Eczematous
- Secondary Impetiginization
- Secondary adrenocortical insufficiency
- Secondary thrombocytopenia
- Serum Sickness
- Skin chapped
- Stomatitis, Denture
- Synovitis
- Systemic Lupus Erythematosus
- Temporal Arteritis
- Tinea Corporis
- Transfusion Reactions
- Trichinosis
- Tuberculosis (TB)
- Ulcerative Colitis
- Urticaria
- Uveitis
- Wound Infections
- Acute Bursitis
- Acute Multiple sclerosis
- Acute Rheumatic heart disease, unspecified
- Acute Tenosynovitis
- Corticosteroid-responsive dermatoses
- Cutaneous candidiasis
- Cystic tumour of the ganglia
- Exfoliative erythroderma
- Granuloma annulare lesions
- Idiopathic eosinophilic pneumonias
- Non-suppurative Thyroiditis
- Oral infections
- Oral lesions
- Severe Erythema multiforme
- Subacute Dermatitis, Eczematous
- Symptomatic Sarcoidosis
- Ulceration of the mouth
- Ulcerative stomatitis
Research Report
A Comprehensive Monograph on Triamcinolone (DB00620): Pharmacology, Clinical Efficacy, and Safety Profile
Executive Summary
Triamcinolone is a potent, synthetic glucocorticoid of the pregnane steroid class, representing a significant advancement in anti-inflammatory therapy since its initial U.S. Food and Drug Administration (FDA) approval on December 3, 1957.[1] As a derivative of cortisol, it is engineered to maximize anti-inflammatory and immunosuppressive activity while minimizing the mineralocorticoid effects associated with earlier corticosteroids.[3] Its primary clinical value lies in its ability to powerfully modulate the immune system and control inflammation across a wide spectrum of diseases.
The pharmacological activity of Triamcinolone is mediated through its function as a high-affinity agonist for intracellular glucocorticoid receptors.[1] Upon binding, the activated drug-receptor complex translocates to the nucleus, where it modulates gene expression. This genomic mechanism has a dual effect: it upregulates the synthesis of anti-inflammatory proteins, such as lipocortin-1, and simultaneously represses the transcription of pro-inflammatory genes by inhibiting key pathways involving transcription factors like nuclear factor-kappa B (NF-κB). The net result is a profound suppression of the inflammatory cascade, including the inhibition of critical mediators like prostaglandins, leukotrienes, and a host of pro-inflammatory cytokines.[6]
Clinical Trials
View More Clinical Trials
Sign in to access the complete clinical trial database with detailed study information.
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2024/03/27 | Not Applicable | Completed | Pia Lopez Jornet | ||
2024/03/25 | Not Applicable | Recruiting | |||
2024/03/13 | Phase 4 | Completed | |||
2024/03/01 | Phase 3 | Completed | Police General Hospital, Thailand | ||
2024/02/28 | Phase 4 | Recruiting | Phramongkutklao College of Medicine and Hospital | ||
2024/02/21 | Phase 3 | Recruiting | |||
2024/02/01 | Phase 2 | Recruiting | Marie Badalamente | ||
2024/01/30 | Phase 1 | Not yet recruiting | |||
2024/01/24 | Not Applicable | Completed | Taipei Medical University Shuang Ho Hospital | ||
2024/01/12 | Not Applicable | Completed | Haydarpasa Numune Training and Research Hospital |
FDA Drug Approvals
View More FDA Approvals
Sign in to access additional FDA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| A-S Medication Solutions | 50090-5980 | TOPICAL | 5 mg in 1 g | 8/9/2023 | |
| Bryant Ranch Prepack | 63629-8688 | TOPICAL | 1 mg in 1 g | 1/20/2022 | |
| Bryant Ranch Prepack | 63629-2406 | TOPICAL | 0.147 mg in 1 g | 2/23/2021 | |
| Physicians Total Care, Inc. | 54868-1591 | TOPICAL | 1 mg in 1 g | 2/23/2011 | |
| Preferred Pharmaceuticals Inc | 68788-7814 | DENTAL | 1 mg in 1 g | 10/6/2023 | |
| AuroMedics Pharma LLC | 55150-384 | INTRAMUSCULAR, INTRA-ARTICULAR, SOFT TISSUE | 40 mg in 1 mL | 4/8/2019 | |
| Eugia US LLC | 55150-384 | INTRAMUSCULAR, INTRA-ARTICULAR, SOFT TISSUE | 40 mg in 1 mL | 4/8/2019 | |
| E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. | 0168-0003 | TOPICAL | 0.25 mg in 1 g | 3/1/2018 | |
| NorthStar RxLLC | 16714-987 | TOPICAL | 5 mg in 1 g | 12/25/2023 | |
| Glenmark Pharmaceuticals Inc., USA | 68462-314 | TOPICAL | 1 mg in 1 g | 1/31/2021 |
EMA Drug Approvals
View More EMA Approvals
Sign in to access additional EMA-approved drug information with detailed regulatory data.
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
View More HSA Approvals
Sign in to access additional HSA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
View More NMPA Approvals
Sign in to access additional NMPA-approved drug information with detailed regulatory data.
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Triamcinolone Acetonide Acetate Cream | 国药准字H13022077 | 化学药品 | 乳膏剂 | 9/20/2020 | |
| Triamcinolone Acetonide Acetate Cream | 国药准字H41025596 | 化学药品 | 乳膏剂 | 6/24/2020 | |
| Triamcinolone Acetonide Acetate Cream | 国药准字H12020638 | 化学药品 | 乳膏剂 | 3/19/2020 | |
| Triamcinolone Acetonide Acetate Cream | 国药准字H34020377 | 化学药品 | 乳膏剂 | 5/14/2024 | |
| Triamcinolone Acetonide Acetate Cream | 国药准字H33020649 | 化学药品 | 乳膏剂 | 7/6/2020 | |
| Triamcinolone Acetonide Acetate Cream | 国药准字H35020047 | 化学药品 | 乳膏剂 | 12/10/2020 | |
| Triamcinolone Acetonide Acetate Cream | 国药准字H44023917 | 化学药品 | 乳膏剂 | 3/9/2020 | |
| Triamcinolone Acetonide Acetate Cream | 国药准字H37021966 | 化学药品 | 乳膏剂 | 2/19/2020 | |
| Triamcinolone Acetonide Injection | 国药准字H53021605 | 化学药品 | 注射剂 | 8/19/2020 | |
| Triamcinolone Acetonide Injection | 国药准字HJ20160057 | 化学药品 | 注射剂 | 12/3/2021 |
PPB Drug Approvals
View More PPB Approvals
Sign in to access additional PPB-approved drug information with detailed regulatory data.
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| CHI-CREAM | N/A | N/A | N/A | 1/14/1997 | |
| TRIZOL-N CREAM | N/A | N/A | N/A | 1/24/1992 | |
| PINOCINE KENIL CREAM | N/A | N/A | N/A | 1/14/1997 | |
| FUHARKIN CREAM | N/A | N/A | N/A | 1/14/1997 | |
| PAFULIMA CREAM | N/A | N/A | N/A | 2/8/1996 | |
| TRIMAX CREAM | N/A | N/A | N/A | 12/2/2004 | |
| SINOCORT CREAM | N/A | N/A | N/A | 2/8/1996 | |
| TRIDAZINE CREAM | N/A | N/A | N/A | 2/8/1996 | |
| ECONSONE CREAM | N/A | N/A | N/A | 11/12/1982 | |
| SEATTLE CREAM | N/A | N/A | N/A | 12/29/2004 |
TGA Drug Approvals
View More TGA Approvals
Sign in to access additional TGA-approved drug information with detailed regulatory data.
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.